---
title: "Hoth Therapeutics (HOTH.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HOTH.US/norm.md"
symbol: "HOTH.US"
name: "Hoth Therapeutics"
parent: "https://longbridge.com/en/quote/HOTH.US.md"
datetime: "2026-05-20T11:33:05.207Z"
locales:
  - [en](https://longbridge.com/en/quote/HOTH.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HOTH.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HOTH.US/norm.md)
---

# Hoth Therapeutics (HOTH.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.1705 | -0.1720 | -0.2978 | -0.1669 | -0.2731 |
| ROE | -208.88% | -149.52% | -182.73% | -82.67% | -150.97% |
| Revenue | - | - | - | - | - |
| Net income | -2.69M | -2.69M | -4.11M | -2.20M | -3.48M |
| Operating income | -2.65M | -2.61M | -4.08M | -2.20M | -3.48M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 5.59M | 7.60M | 9.24M | 10.11M | 12.36M |
| Leverage | 1.34 | 1.24 | 1.12 | 1.04 | 1.07 |
| BVPS | 0.2558 | 0.3965 | 0.5442 | 0.7362 | 0.8762 |
| Turnover | - | - | - | - | - |
| Cash & STI | 4.05M | 6.25M | 7.85M | 9.01M | 11.32M |
| Inv & Rec | - | - | - | - | - |
| LT assets | - | 4652.00 | 11464.00 | 18081.00 | 24509.00 |
| Net debt | -4.05M | -6.24M | -7.83M | -8.99M | -11.29M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -3.05M | -2.15M | -2.49M | -2.37M | -2.79M |
| Investing CF | 147202.00 | 0.0000 | -300000.00 | - | - |
| Financing CF | 701484.00 | 550138.00 | 1.63M | 66101.00 | 7.07M |
| Free CF | -1.87M | -584197.00 | -807900.00 | -1.82M | -2.34M |
| OCF coverage | - | - | - | - | - |
| Repaid & issued | - | - | - | - | - |
| CapEx | - | - | - | - | - |